21 November 2023 : Original article
Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors
Mikołaj Kuncewicz
1BCDEF, Igor Piotr Jaszczyszyn 1BCDE, Kacper Karaban 1BCDE, Paweł Rykowski 1DEF*, Maciej Krasnodębski 1ADE, Marcin Morawski 1EF, Emilia Kruk 1B, Łukasz Koperski 2BC, Krzysztof Zieniewicz 1EF, Marek Krawczyk 1AEF, Michał Grąt 1AEF
DOI: 10.12659/AOT.941212
Ann Transplant 2023; 28:e941212
Table 3 Characteristics of the study group.
| Number of missing data (%) | Median or number | Range or % | |
|---|---|---|---|
| Follow-up (months) | 0 (0%) | 72.5 | 0.3–235.1 |
| Recipient Gender | 0 (0%) | ||
| Female | 11 | 57.89% | |
| Male | 8 | 42.11% | |
| Recipient BMI | 4 (21.05%) | 24.9 | 17.2–31.0 |
| Recipient age (y) | 0 (0%) | 51 | 27–66 |
| Donor age (y) | 1 (5.26%) | 46 | 20–75 |
| Time from primary lesion resection (months) | 4 (21.05%) | 19.5 | 1–82 |
| Systemic treatment prior to LT | 0 (0%) | 15 | 78.95% |
| Surgical treatment prior to LT | 0 (0%) | 9 | 47.37% |
| LR | 3 | 33.33% | |
| RFA | 3 | 33.33% | |
| LR+RFA | 1 | 11.11% | |
| TACE | 2 | 22.22% | |
| Caval anastomosis | 0 (0%) | ||
| Piggy-back | 6 | 31.58% | |
| Classic | 13 | 68.42% | |
| Biliary anastomosis | 0 (0%) | ||
| End-to-end | 17 | 89.47% | |
| Roux-en-Y | 2 | 10.53% | |
| PRBC transfusions (U) | 1 (5.26%) | 2.5 | 0–10 |
| Primary tumor site | 0 (0%) | ||
| Pancreas | 8 | 42.11% | |
| Small bowel | 6 | 31.58% | |
| Colon | 3 | 15.79% | |
| Stomach | 1 | 5.26% | |
| Unknown | 1 | 5.26% | |
| Extrahepatic metastases in history (previously resected) | 0 (0%) | 7 | 36.84% |
| Abdominal lymph nodes | 5 | 71.43% | |
| Abdominal lymph nodes+mediastinum | 1 | 14.29% | |
| Peritoneum | 1 | 14.29% | |
| Extent of liver involvement (%) | 3 (15.79%) | 7.5 | 1–60 |
| Number of tumors | 0 (0%) | ||
| Numerous | 13 | ||
| Countable | 6 | ||
| Number of countable tumors | 1 (5.26%) | 4 | 2–4 |
| Size of tumor (mm) | 0 (0%) | 2–200 | |
| Ki67 index (%) | 0 (0%) | 2 | 2–16 |
| Mitotic index | 0 (0%) | 1 | 0–10 |
| MELD | 0 (0%) | 7 | 6–18 |
| Cold ischemia (min) | 0 (0%) | 510 | 240–720 |
| BMI – body mass index; LT – liver transplantation; LR – liver resection; RFA – radiofrequency ablation; TACE – transarterial chemoembolization; PRBC – packed red blood cells; MELD – model for end-stage liver disease. | |||